Revealed by the Gamalaya Institute
MOSCOW: The latest results of the Russian-developed Sputnik-V vaccine have once again revealed 91.4 percent efficacy. The Gamalea Institute released its latest statement after analyzing the data of nearly 22,000 volunteers who took part in the third phase of clinical trials.
The Sputnik-V vaccine was found to be 91.4 percent effective 21 days after the first dose. The data of 22,714 volunteers who had recently taken two doses were analyzed after 21 days. It was later revealed that 78 of them were infected with the virus. However, the Gamleya Institute revealed that 62 of the 78 people infected with the virus belonged to the placebo group. The developers of Sputnik-V said in an official statement that the latest results prove that their vaccine is more than 90 percent effective.
Sputnik has already made it clear that the vaccine is 100 percent effective in more severe cases. As part of the analysis, 20 of the volunteers became seriously ill. All of them belonged to the placebo group. None of those who took the vaccine reported severe symptoms. According to Gamaleya, the interim results on the effectiveness of the vaccine were calculated in three stages, according to the terms of the third stage clinical trials. Vaccine revealed that those who took placebo were evaluated once in 20 cases, 39 cases again, and 78 cases when their efficacy was evaluated. As part of the third phase of clinical trials, the vaccine was given to 26,000 people in Russia alone.
Read these ..
Over the next 4-6 months the corona will become more intense-billgates
Lockdown again in Germany